Skip to main content
Fig. 1 | European Journal of Medical Research

Fig. 1

From: Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19

Fig. 1

SARS-CoV-2 viral protein-specific antibody levels in plasma drawn up to 250 days following the end of the symptoms from individuals with different disease severity. Disease severity was according to WHO classification (Blue indicates WHO °1, green WHO °2, gold WHO °3). Shown are the results of the first blood draw after including the individual into the study. A S1 protein-specific IgA antibody levels, measured with the Euroimmun assay. Results are expressed as ratio. B S1 protein-specific IgG antibody levels, measured with the Euroimmun assay. Results are expressed as ratio. C Nucleocapsid (N)-specific IgG antibody levels measured with the Euroimmun assay. Results are expressed as ratio. D N-specific Ig antibody levels detected with Elecsys®, Roche. E The SARS-CoV-2 serum neutralization titer, determined by microscopic inspection as the highest serum dilution without virus-induced cytopathic effect. Outliers are presented as circles (more than 1.5 IQR out of the box) or stars (more than 3 IQR out of the box). Day after end of symptoms was divided into quartiles (d20 to d31, d32-d47, d48-d76, > d77, range between d20 to d120)

Back to article page